Tirzepatide Dosage Guide for Research
This guide provides researchers with comprehensive dosage reference information for tirzepatide, the dual GIP/GLP-1 receptor agonist. All dosing data is derived from published clinical trial protocols, primarily the SURMOUNT and SURPASS trial programs.
Standard Titration Schedule
The SURMOUNT/SURPASS titration protocol follows a 4-week dose-escalation schedule:
| Week | Dose | Duration | Purpose |
|---|---|---|---|
| 1-4 | 2.5 mg | 4 weeks | Initiation |
| 5-8 | 5.0 mg | 4 weeks | Escalation 1 |
| 9-12 | 7.5 mg | 4 weeks | Escalation 2 |
| 13-16 | 10.0 mg | 4 weeks | Escalation 3 |
| 17+ | 15.0 mg | Maintenance | Target dose |
Note: In clinical trials, three target maintenance doses were studied: 5mg, 10mg, and 15mg. The titration continues until the assigned target dose is reached.
Reconstitution Guide
Lyophilized tirzepatide requires reconstitution with bacteriostatic water before use.
Concentration Table (5mg Vial)
| BAC Water | Concentration | 2.5mg Dose | 5mg Dose |
|---|---|---|---|
| 1.0 mL | 5.0 mg/mL | 50 units | 100 units (full syringe) |
| 2.0 mL | 2.5 mg/mL | 100 units | N/A (exceeds syringe) |
Concentration Table (10mg Vial)
| BAC Water | Concentration | 2.5mg | 5mg | 7.5mg | 10mg |
|---|---|---|---|---|---|
| 1.0 mL | 10 mg/mL | 25 units | 50 units | 75 units | 100 units |
| 2.0 mL | 5.0 mg/mL | 50 units | 100 units | N/A | N/A |
Concentration Table (15mg Vial)
| BAC Water | Concentration | 5mg | 10mg | 15mg |
|---|---|---|---|---|
| 1.5 mL | 10 mg/mL | 50 units | 100 units | N/A |
| 3.0 mL | 5.0 mg/mL | 100 units | N/A | N/A |
Clinical Trial Results by Dose
Weight Reduction (SURMOUNT-1, 72 weeks)
| Dose | Mean Weight Loss | ?5% Loss | ?10% Loss | ?20% Loss |
|---|---|---|---|---|
| 5 mg | -15.0% | 85% | 69% | 32% |
| 10 mg | -19.5% | 89% | 79% | 46% |
| 15 mg | -20.9% | 91% | 84% | 57% |
| Placebo | -3.1% | 35% | 14% | 1.5% |
HbA1c Reduction (SURPASS-2, 40 weeks)
| Dose | HbA1c Reduction | vs Semaglutide 1mg |
|---|---|---|
| 5 mg | -2.01% | Superior |
| 10 mg | -2.24% | Superior |
| 15 mg | -2.37% | Superior |
| Semaglutide 1mg | -1.86% | — |
Pharmacokinetic Parameters
- Half-life: ~5 days (120 hours)
- Tmax: 8-72 hours post-injection
- Steady state: Reached after 4 weeks of weekly dosing
- Route: Subcutaneous injection (abdomen, thigh, or upper arm)
- Administration: Once weekly, any time of day, regardless of meals
Dose Calculation Formula
Volume (mL) = Desired Dose (mg) ÷ Concentration (mg/mL)
Example: For a 7.5mg dose from a 10mg/mL solution:
7.5 ÷ 10 = 0.75 mL = 75 units on an insulin syringe
See our complete dosage calculation guide and reconstitution guide for step-by-step instructions.
Comparison with Semaglutide Dosing
| Parameter | Tirzepatide | Semaglutide |
|---|---|---|
| Starting dose | 2.5 mg/week | 0.25 mg/week |
| Max research dose | 15 mg/week | 2.4 mg/week |
| Titration period | 16 weeks | 16 weeks |
| Half-life | ~5 days | ~7 days |
| Frequency | Once weekly | Once weekly |
For a full comparison, see semaglutide vs tirzepatide.
Frequently Asked Questions
What is the highest dose of tirzepatide studied?
15mg once weekly is the highest dose used in Phase 3 clinical trials (SURMOUNT and SURPASS programs).
Can the titration be slowed down?
Yes. Some protocols extend the escalation period at each dose if tolerability is a concern. Each dose level can be maintained for longer than 4 weeks before escalating.
What is the most common side effect limiting dose escalation?
Nausea is the most frequently reported dose-limiting side effect, occurring in 12-33% of participants across dose levels in SURMOUNT trials. It typically peaks during dose escalation and diminishes during maintenance.
Related Articles
- What is Tirzepatide?
- Tirzepatide: Complete Research Guide
- Semaglutide Dosage Chart
- Semaglutide vs Tirzepatide
All products sold by Proxiva Labs are intended for research and laboratory use only. Not for human consumption.
All products are sold strictly for research purposes only. Not for human consumption.